» Articles » PMID: 35707056

COVID-19 Vaccination in Pediatric Population: A Necessity or Obstruction to the Protection of the Right to Health? Biojuridical Perspective

Overview
Specialty Public Health
Date 2022 Jun 16
PMID 35707056
Authors
Affiliations
Soon will be listed here.
Abstract

One of the most recently debated topics worldwide is the mass vaccination of children against coronavirus disease 2019 (COVID-19). Next, the risk/benefit ratio of COVID-19 vaccination and infection in children are compared. Nonetheless, the real question in this debate is as follows: Does the vaccine represent a necessary tool or is it an obstacle in protecting the right to health? From a public health point of view, the Supreme Court of Nova Scotia, in Canada, recommends COVID-19 vaccination in the pediatric population. Based on Article 25 of the Draft Articles on State responsibility, vaccination can be considered a social act necessary for protecting the individual's right to health. The 1989 New York Convention on the Rights of the Child and the European Regulation number 219/1111 state that the opinion of a minor aged >12 years is considerable. However, this validity of opinion is related to age and degree of discernment. The onset of adverse events following the administration of the COVID-19 vaccine may lead to compensation in the near future. Recent studies have identified a new COVID-19-related pediatric pathology, known as multisystem inflammatory syndrome. Other studies have demonstrated that myocarditis in the pediatric population might occur following COVID-19 vaccine administration. In June 2021 in the USA, the Center for Control and Prevention of Infectious Diseases Advisory Committee on Immunization Practices declared that the benefits of vaccination against COVID-19 in the pediatric population outweighed the risks. In the meantime, whereas the bioethical debate remains open, monitoring the real risk/benefit ratio of vaccination in the pediatric population is crucial.

Citing Articles

Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance.

Ferreira-da-Silva R, Lobo M, Pereira A, Morato M, Polonia J, Ribeiro-Vaz I Front Med (Lausanne). 2025; 12:1501921.

PMID: 40046918 PMC: 11879978. DOI: 10.3389/fmed.2025.1501921.


Anti-SARS-CoV-2 Vaccination and PIMS-TS-Friends or Foe? Case Reports and Literature Review.

Opoka-Winiarska V, Morawska-Michalska I, Mertowska P, Gosik K, Kadziolka O, Grywalska E Vaccines (Basel). 2024; 12(3).

PMID: 38543912 PMC: 10975931. DOI: 10.3390/vaccines12030278.


Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia.

Lassanova M, Lassan S, Liskova S, Tesar T, Cicova M Front Pharmacol. 2023; 14:1097890.

PMID: 36726587 PMC: 9886282. DOI: 10.3389/fphar.2023.1097890.


Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries.

Bots S, Riera-Arnau J, Belitser S, Messina D, Aragon M, Alsina E Front Pharmacol. 2022; 13:1038043.

PMID: 36506571 PMC: 9730238. DOI: 10.3389/fphar.2022.1038043.

References
1.
Prestileo T, Argo A, Triolo V, Zerbo S, Procaccianti P . [Informed consent for HIV diagnostic tests: what to do in case of minors]. Infez Med. 2009; 16(4):200-3. View

2.
Levy-Bruhl D, Fonteneau L, Vaux S, Barret A, Antona D, Bonmarin I . Assessment of the impact of the extension of vaccination mandates on vaccine coverage after 1 year, France, 2019. Euro Surveill. 2019; 24(26). PMC: 6607743. DOI: 10.2807/1560-7917.ES.2019.24.26.1900301. View

3.
Lopman B, Payne D, Tate J, Patel M, Cortese M, Parashar U . Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Curr Opin Virol. 2012; 2(4):434-42. DOI: 10.1016/j.coviro.2012.05.002. View

4.
Hause A, Gee J, Baggs J, Abara W, Marquez P, Thompson D . COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(31):1053-1058. PMC: 8367318. DOI: 10.15585/mmwr.mm7031e1. View

5.
Principi N, Esposito S . Reasons in favour of universal vaccination campaign against COVID-19 in the pediatric population. Ital J Pediatr. 2022; 48(1):4. PMC: 8743738. DOI: 10.1186/s13052-021-01192-4. View